'Team Frenchie' has coach's back Seattle Post Intelligencer - "I don't have cancer!" French responded, humored by the impertinent question. Three days of drugs didn't work. French, 31, noticed she now felt dizzy when ...
Head and Neck Cancer Is Treatable in Elderly Patients Cancer Consultants, ID - Nov 26, 2008 Patients 80 years or older with Stage I-II head and neck cancer have good outcomes following surgery or radiation therapy, according to the results of a ...
Survival Of Head And Neck Cancer Patients Is Greatly Affected By ... Science Daily (press release) - Nov 19, 2008 19, 2008) ? Current estimates for head and neck cancer survival are largely inaccurate because they widely disregard many of the most common diseases such ...
Child's cancer treatment spans two worlds Anchorage Daily News, AK - Nov 30, 2008 An amulet containing stones from Laos hangs from Ryan Lee's neck to promote healing as he visits the Pediatric Oncology Infusion Center. ...
Head & neck are also prime targets for tobacco New York Daily News, NY - Nov 26, 2008 The most common head and neck cancers occur in the thyroid, oral cavity, and larynx; of the three, only thyroid cancer is not linked to smoking. ...
Free clinic in Fort Collins will screen for head, neck cancer ReporterHerald.com, CO - Nov 14, 2008 By Shelley Widhalm Donna Hinz of Loveland likes to help out at the annual Northern Colorado Head and Neck Cancer Screening, which will be this Saturday, ...
Source: Google News
Recent News and Articles on the Keywords: neck cancer + extends survival + cancer Related to the article below (Last Update: 8/7/2008)
Q&A: HPV vaccination Irish Times, Ireland - Aug 5, 2008 HPV infection is found in 99 per cent of women with cervical cancer. Cancer of the neck of the womb is diagnosed in almost 200 women here every year. ...
The chef with no taste guardian.co.uk, UK - Jul 19, 2008 The prognosis for people with stage four head-and-neck cancer has not been good: for those with cancer like Achatz's, survival rates after three years can ...
ImClone Announces Changes in Commercial Organization Leadership Business Wire (press release), CA - Jul 14, 2008 Carefully consider the use of ERBITUX in combination with radiation therapy in head and neck cancer patients with a history of coronary artery disease, ...IMCL
Environment Becomes Heredity Miller-McCune.com, CA - Jul 17, 2008 Even the breast cancer genes that confer horrifyingly high risk on women who carry them don?t absolutely doom those women to breast cancer, and many people ...
Head and neck cancer - EE Vokes, RR Weichselbaum, SM Lippman? - Textbook of Medical Oncology, 2000 - books.google.com ... cricoid or thyroid cartilage and/or extends to other ... major threat to the long-term survival of patients with early-stage head and neckcancer, and are ...
[CITATION] Exercise in Cancer Survivors: An Overview of Research. - KS COURNEYA - Medicine & Science in Sports & Exercise, 2003 ... examined prostate cancer survivors (40), head/neckcancer survivors (61 ... the risk
of recurrence, other diseases, or extendsurvival after a cancer diagnosis ...
Head and neck cancer: treatment with Erbitux extends survival
The FDA ( U.S. Food and Drug Administration ) approved Erbitux ( Cetuximab ) for use in combination with radiation therapy to treat patients with squamous cell cancer of the head and neck ( SCCHN ) that can not be removed by surgery.
Erbitux, which received a priority review, is the first drug approved to treat head and neck cancer since methotrexate became available in the 1950s.
Approval of Erbitux in combination with radiation therapy was based on a study that showed it prolonged survival by 20 months compared to treatment with radiation alone.
Approval of Erbitux monotherapy was based on evidence of tumor shrinkage in 13 percent of patients, lasting on average of 6 months.
Standard cancer statistics databases estimate that there are about 29,000 new cases of head and neck cancer diagnosed every year in the United States.
The safety and effectiveness of Erbitux was established in two studies.
The randomized clinical trial of 424 patients using Erbitux in combination with radiation therapy showed a survival time of 49 months versus 29.3 months on radiation therapy alone.
In addition, delay in tumor growth was observed with the use of Erbitux and radiation, compared to radiation alone.
In a second trial of 103 patients with recurrent or metastatic SCCHN, Erbitux helped to shrink the tumors after the tumors no longer responded to platinum-based therapy, the current standard treatment for patients with this difficult to treat disease.
Commonly reported side effects of Erbitux were infusion reactions ( fever, chills ), skin rash, fatigue/malaise, nausea.
The common side effects associated with radiation such as sore mouth, trouble swallowing, and radiation skin changes were similar in frequency in patients receiving Erbitux plus radiation and those receiving radiation alone.
